Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland

Serban Radian,Yoan Diekmann,Plamena Gabrovska,Brendan Holland,Lisa Bradley,Helen Wallace,Karen Stals,Anna-Marie Bussell,Karen McGurren,Martin Cuesta,Anthony W Ryan,Maria Herincs,Laura C Hernández-Ramírez,Aidan Holland,Jade Samuels,Elena Daniela Aflorei,Sayka Barry,Judit Dénes,Ida Pernicova,Craig E Stiles,Giampaolo Trivellin,Ronan McCloskey,Michal Ajzensztejn,Noina Abid,Scott A Akker,Moises Mercado,Mark Cohen,Rajesh V Thakker,Stephanie Baldeweg,Ariel Barkan,Madalina Musat,Miles Levy,Stephen M Orme,Martina Unterländer,Joachim Burger,Ajith V Kumar,Sian Ellard,Joseph McPartlin,Ross McManus,Gerard J Linden,Brew Atkinson,David J Balding,Amar Agha,Chris J Thompson,Steven J Hunter,Mark G Thomas,Patrick J Morrison,Márta Korbonits
DOI: https://doi.org/10.1002/humu.23121
Abstract:The aryl hydrocarbon receptor interacting protein (AIP) founder mutation R304* (or p.R304* ; NM_003977.3:c.910C>T, p.Arg304Ter) identified in Northern Ireland (NI) predisposes to acromegaly/gigantism; its population health impact remains unexplored. We measured R304* carrier frequency in 936 Mid Ulster, 1,000 Greater Belfast (both in NI) and 2,094 Republic of Ireland (ROI) volunteers and in 116 NI or ROI acromegaly/gigantism patients. Carrier frequencies were 0.0064 in Mid Ulster (95%CI = 0.0027-0.013; P = 0.0005 vs. ROI), 0.001 in Greater Belfast (0.00011-0.0047) and zero in ROI (0-0.0014). R304* prevalence was elevated in acromegaly/gigantism patients in NI (11/87, 12.6%, P < 0.05), but not in ROI (2/29, 6.8%) versus non-Irish patients (0-2.41%). Haploblock conservation supported a common ancestor for all the 18 identified Irish pedigrees (81 carriers, 30 affected). Time to most recent common ancestor (tMRCA) was 2550 (1,275-5,000) years. tMRCA-based simulations predicted 432 (90-5,175) current carriers, including 86 affected (18-1,035) for 20% penetrance. In conclusion, R304* is frequent in Mid Ulster, resulting in numerous acromegaly/gigantism cases. tMRCA is consistent with historical/folklore accounts of Irish giants. Forward simulations predict many undetected carriers; geographically targeted population screening improves asymptomatic carrier identification, complementing clinical testing of patients/relatives. We generated disease awareness locally, necessary for early diagnosis and improved outcomes of AIP-related disease.
What problem does this paper attempt to address?